Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2016
More options to be made available to treat hepatitis C
9 September 2016 - Another ‘potential curative’ drug for people with chronic hepatitis C will be made available on the NHS. ...
Posted by Michael Wonder on 09 Sep 2016
Confirmed prices for 2016 October cycle
9 September 2016 - Confirmed 1 October 2016 prices resulting from the 2016 October cycle of price disclosure have now been ...
Posted by Michael Wonder on 09 Sep 2016
Proposal relating to two HIV treatments (Tivicay and Kivexa)
9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...
Posted by Michael Wonder on 08 Sep 2016
Coil is more effective than pill as emergency contraception, says NICE
8 September 2016 - NICE is calling for women to be told that the coil is more effective than the ‘morning ...
Posted by Michael Wonder on 08 Sep 2016
Access to Medicines Working Group communiques
8 September 2016 - The communiques from the February 2015, September 2015 and April 2016 meetings of the Access to Medicines ...
Posted by Michael Wonder on 07 Sep 2016
Eribulin in liposarcoma: added benefit not proven
1 September 2016 - Neither results from a study of direct comparison nor from an indirect comparison were suitable. ...
Posted by Michael Wonder on 07 Sep 2016
IQWiG Autumn Symposium 2016: programme is now online
6 September 2016 - More light than shadow? Beneficial and hindering factors for successful clinical studies. ...
Posted by Michael Wonder on 06 Sep 2016
NICE rejects Roche’s melanoma combination
6 September 2016 - Patients in England and Wales with melanoma will not be getting routine access to Roche's Cotellic/Zelboraf combination ...
Posted by Michael Wonder on 05 Sep 2016
Australian Statistics on Medicines 2015
5 September 2016 - The Australian Statistics on Medicines for 2015 are now available. ...
Posted by Michael Wonder on 05 Sep 2016
Eisai bewildered as Germany's IQWIG fails to recognise additional benefit of Halaven (eribulin mesylate) in the treatment of advanced liposarcoma
4 September 2016 - Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcoma. ...
Posted by Michael Wonder on 05 Sep 2016
PHARMAC’s implementation of Trans-Pacific Partnership provisions and other amendments to application processes
5 September 2016 - PHARMAC is seeking feedback on our proposed approach to addressing New Zealand’s obligations under the Trans-Pacific Partnership ...
Posted by Michael Wonder on 05 Sep 2016
Proposal related to second & third-line anti-VEGF treatments for ophthalmic use
5 September 2016 - PHARMAC has entered into provisional agreements with Novartis and Bayer and is seeking feedback on a ...
Posted by Michael Wonder on 05 Sep 2016
Help shape the way PHARMAC implements TPP changes
5 September 2016 - PHARMAC is asking New Zealanders to help it make some changes to how medicine and medical device ...
Posted by Michael Wonder on 03 Sep 2016
NICE recommends Cancer Drugs Fund treatment for prostate cancer for routine NHS use
2 September 2016 - More prostate cancer patients will receive radium 223 after NICE approved it for routine NHS use. ...
Posted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...